Latest filing published 06 Nov 2017 for Viracta Therapeutics, Inc., €56k.
Filing timeline
BuySaleInsider track record
Closed purchases
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
MPM Oncology Impact Management GP LLC: trading record in brief
MPM Oncology Impact Management GP LLC discloses dealings in Viracta Therapeutics, Inc. to SEC (Form 4). We count 3 filings; the first trade dates from 2 November 2017 and the latest from 6 November 2017.
The open-market record is one-sided, with 3 purchases worth €194k and not one sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay.
The median purchase comes to €56k. 3 out of 3 purchases came within 30 days of a purchase by at least one other insider of the same company. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.
Most recently, on 6 November 2017, the filings show an open-market purchase worth €56k in Viracta Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 3 days. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to MPM Oncology Impact Management GP LLC
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 25,300 shares@ US$2.5929.0% of flowCommon StockSEC:0001140361-17-041187:0Canonical exit: 31 Jan 2018 (T+90)
- 40,000 shares@ US$2.8951.1% of flowCommon StockSEC:0001140361-17-041187:1Canonical exit: 1 Feb 2018 (T+90)
- 16,200 shares@ US$2.7719.9% of flowCommon StockSEC:0001140361-17-041187:2Canonical exit: 4 Feb 2018 (T+90)
3 of 3 declarations
